BRCA2在卵巢肿瘤组织中的表达及临床意义  

Expression of BRCA2 in ovarian tumor tissues and its clinical significance

作　　者：刘琼琼[1] 张慧林[2] 李琥[1] 张万东[2] 王小英[1] 李凤山[2] 冯振卿[1] 朱进[1,3] 

机构地区：[1]南京医科大学卫生部抗体技术重点实验室,江苏南京210029 [2]南京医科大学附属南京市妇幼保健院,江苏南京210004 [3]南京军区军事医学研究所,江苏南京210002

出　　处：《南京医科大学学报（自然科学版）》2012年第7期995-999,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：南京市卫生局重点项目(YKK08118);南京市科技发展项目(200901083)

摘　　要：目的:乳腺癌易感基因2(breast cancer suscepbility gene 2,BRCA2)是近几年发现的新的抑癌基因,本研究旨在分析BRCA2在卵巢癌组织中的表达及其临床意义。方法:采用1对引物扩增BRCA2基因第14外显子,应用聚合酶链反应和基因测序技术检测BRCA2基因,并且应用免疫组化和Western blot检测肿瘤组织BRCA2蛋白的表达。结果:卵巢黏液性囊腺瘤和正常组织BRCA2基因未发生突变,浆液性肿瘤和黏液性囊腺癌的BRCA2第14外显子的128位碱基T突变为C。Western blot检测结果显示BRCA2在卵巢囊腺癌上的表达低于正常卵巢组织和卵巢囊腺瘤,免疫组化检测结果发现BRCA2在卵巢黏液性囊腺瘤和黏液性囊腺癌中的阳性率分别为87.50%和53.33%,差异有统计学意义(P<0.05);而BRCA2在卵巢浆液性囊腺瘤和浆液性囊腺癌中阳性率分别为53.85%和73.17%,差异没有统计学意义(P>0.05)。BRCA2蛋白在不同年龄、组织学分型、分化程度和临床分期各组间差异均无统计学意义(P>0.05)。结论:BRCA2在卵巢癌组织中的表达不仅可以用于诊断,也可能为治疗提供一个途径。Objective：To analyze expression of breast cancer suscepbility gene 2（BRCA2） in ovarian cancer tissues and its clinical significance. Methods：BRCA2 was detected using a pair of primer on 14 exon of BRCA2 by polymerase chain reaction amplification, and the mutations of BRCA2 were analyzed by DNA sequencing. The expression of BRCA2 protein in ovarian tumor tissues were detected by immunohistochemistry and Western blot. Results：No mutation was found in any mucinous cystadenoma and normal tissues,but the base T of 128 mutated C in 14 exon of BRCA2 in serous tumors and mucinous carcinoma. Western blot showed that BRCA2 protein expression of the malignant tumor in ovarian was lower than that of normal tissues and benign tumors. The results of immunohistochemistry showed that the BRCA2 expression rates in mucinous cystadenoma and mucinous carcinoma were 87.50% and 53.33% respectively,and there were significant differences between the mucinons cystadenoma and mncinous carcinoma （P 〈 0.05）; whereas the BRCA2 expression rates in serous cystadenoma and serous carcinoma were 53.85% and 73.17% respectively,and there was no significant difference between the serous eystadenoma and serous carcinoma （P 〉 0.05）. The BRCA2 expression was not significantly associated with patient＇s age,clinical stage,differentiation and histological types of ovarian cancer （P 〉 0.05）. Conclusion：BRCA2 expression in ovarian tumor tissues can be used as a diagnosis marker,it also may provide a target for the ovarian cancer treatment.

关 键 词：卵巢癌 BRCA2基因 DNA测序 免疫组化 

分 类 号：R737.31[医药卫生—肿瘤]